|
Post by Macgruber on Aug 7, 2015 14:35:17 GMT
Looking pretty rough here after the earnings call. Does anyone see this as a good opportunity to take a position? It seems like there isnt much more hanging out there that could drive the price lower as we await news on the partnership. Any thoughts here guys?
|
|
|
Post by jckrdu on Aug 7, 2015 15:51:15 GMT
Looking pretty rough here after the earnings call. Does anyone see this as a good opportunity to take a position? It seems like there isnt much more hanging out there that could drive the price lower as we await news on the partnership. Any thoughts here guys? Agree this is a good entry point (low $1.20s) for anyone wanting to start a position, or add... as I agree I don't see much more bad news coming. Call was a disappointment on burn rate, and lack of definitive news on partnership/timing. Recent capital raise was done at $2 with no warrants.
This should pop when the partnership news is announced.... just no telling when that happens.
I lightened up here considerably and rotated elsewhere. Still have a position here waiting on partnership news.
|
|
|
Post by guruzim on Sept 2, 2015 4:25:41 GMT
I missed the $1.20 entry but got in after the CEO bought @ 1.40 or so. Nice direction this has taken recently. I think there's $.10 to gain tomorrow but we'll see...
|
|
|
Post by jckrdu on Sept 2, 2015 10:46:01 GMT
I missed the $1.20 entry but got in after the CEO bought @ 1.40 or so. Nice direction this has taken recently. I think there's $.10 to gain tomorrow but we'll see... I missed the $1.20s as well, but started re-adding to my core position here between $1.40 - $1.50. I have a percentage of my portfolio allocated to companies that I believe will announce partnership news very soon; CLBS & ATHX. When one announces, I'll take profits and move more into the other.
|
|
|
Post by guruzim on Sept 2, 2015 19:25:23 GMT
I'm doing roughly the same - ATHX small position, CLBS small, way too much OCAT sadly. Hopefully something moves soon so I can move that money into the other two - I think all are well positioned for gains at the moment. I'm learning, SLOWLY
|
|
|
Post by jckrdu on Sept 3, 2015 15:03:23 GMT
Overdue for news here. Folks are accumulating in advance.
It'd be nice to see a PR next week to get us back to $2 (the offering price), and then partnership news sometime afterwards to get it back to $3ish.
|
|
|
Post by jckrdu on Sept 9, 2015 15:31:14 GMT
I missed the $1.20 entry but got in after the CEO bought @ 1.40 or so. Nice direction this has taken recently. I think there's $.10 to gain tomorrow but we'll see... I missed the $1.20s as well, but started re-adding to my core position here between $1.40 - $1.50. I have a percentage of my portfolio allocated to companies that I believe will announce partnership news very soon; CLBS & ATHX. When one announces, I'll take profits and move more into the other. CLBS recovering back up close to $2.
Presentation updated on website (link below). Slide #8 shows the 3 programs they're looking to partner. I'm hoping for $3ish on partnership news sometime over the next 90 days.
www.caladrius.com/investors/overview/
|
|
|
Post by guruzim on Sept 9, 2015 16:38:56 GMT
I considered taking this off of the table with a 40% gain, but I tend to agree with your assessment that $3+ is in the cards in the short term, so I'm holding.
It was nice to see it over $2 today though.
|
|
|
Post by jckrdu on Sept 9, 2015 16:44:41 GMT
I considered taking this off of the table with a 40% gain, but I tend to agree with your assessment that $3+ is in the cards in the short term, so I'm holding. It was nice to see it over $2 today though. The terms of the deal will likely drive the level of the spike on the news. I think $3ish is very doable if they announce $10-$20 million or so in non-dilutive up-front cash, with the partnering firm picking up the cost of the trials.
|
|
|
Post by observingthechaos on Sept 16, 2015 7:14:57 GMT
You guys in this long term or are you playing this one?
|
|
|
Post by jckrdu on Sept 16, 2015 11:27:04 GMT
You guys in this long term or are you playing this one? I'm just here for the short term trade on the first partnership news. I may hold some longer term depending upon how much of a move we see on the news. If it only pops to $2.50ish, I may hold a portion longer term.
|
|
|
Post by jckrdu on Sept 22, 2015 12:45:48 GMT
I missed the $1.20s as well, but started re-adding to my core position here between $1.40 - $1.50. I have a percentage of my portfolio allocated to companies that I believe will announce partnership news very soon; CLBS & ATHX. When one announces, I'll take profits and move more into the other. CLBS recovering back up close to $2.
Presentation updated on website (link below). Slide #8 shows the 3 programs they're looking to partner. I'm hoping for $3ish on partnership news sometime over the next 90 days.
www.caladrius.com/investors/overview/
PR out this morning on the first of 3 partnerships I'm expecting to see for CLBS. Today's partnership announcement was for their diabetes program. Good news that this is moving forward, but bad news is the terms of the partnership - no upfront cash, and The Sanford Group only looks to be picking up the cost of the initial 2 trial sites. The PR says they'll be 14-15 trial sites in total, so the implication is that CLBS' burn rate will increase to fund the additional trial sites. Not sure the market is going to like this news.
Hopefully, terms of the limb ischemia partnership to move that trial forward in Japan will have better terms, as I don't see today's news having a positive impact on the pps... today's news could do the opposite.
finance.yahoo.com/news/caladrius-biosciences-sanford-research-establish-113000741.html
|
|
|
Post by jckrdu on Oct 17, 2015 15:34:29 GMT
Liquidated my remaining position here last week to build a cash position as a hedge, as I wait for a binary event to play out in another stock I own. I still like the story here, and intend to re-acquire a position in the weeks/months ahead once the binary event plays out elsewhere. GL all.
|
|
|
Post by jckrdu on Oct 30, 2015 15:41:02 GMT
Restarted a position here at $1.12.
Earnings call is 11/5, where we'll get more clarity on their financial position, burn rate...
Still looking for Japan partnership news before end of year.
|
|
|
Post by jckrdu on Oct 31, 2015 18:15:25 GMT
Below is the link to the pending trial in Japan for limb ischemia. Status: Not Yet Recruiting Health Authority: Japan: Pharmaceuticals and Medical Devices Agency Study Start Date: January 2016 Question is, will Caladrius announce a Japanese partner to get this trial going in Japan? IMO, there's a decent probability they announce a deal before the end of the year as they've been working on it for awhile. The CEO (bio below) was the former President and CEO of Chugai USA, so he certainly has contacts and relationships to move things forward in Japan. clinicaltrials.gov/ct2/show/NCT02501018?term=caladrius&rank=5CEO MazzoDavid J. Mazzo was appointed as Caladrius Biosciences’ Chief Executive Officer and a member of our Board of Directors on January 5, 2015. Dr. Mazzo brings to the Company over 30 years of experience in the pharmaceutical industry. Prior to joining Caladrius (formerly NeoStem), Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the board of directors of Regado Biosciences, Inc., a Nasdaq-listed biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008, Dr. Mazzo was President, Chief Executive Officer and a director of Æterna Zentaris, Inc., a publicly held international biopharmaceutical company. From 2003 until 2007, Dr. Mazzo served as President, Chief Executive Officer and a director of Chugai Pharma USA, LLC, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, which was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulene SA, a French pharmaceuticals company, which was subsequently acquired by Hoechst AG. He currently serves on the boards of directors of pSivida Corp., a publicly held biopharmaceutical company, in the role of non-executive chairman, and Avanir Pharmaceuticals, Inc., a publicly held biopharmaceutical company. Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in analytical chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.
|
|
|
Post by jckrdu on Nov 4, 2015 19:45:36 GMT
Restarted a position here at $1.12. Earnings call is 11/5, where we'll get more clarity on their financial position, burn rate... Still looking for Japan partnership news before end of year. Nice move off of $1.10ish to the $1.35 - $1.40 range where its been consolidating for the past few days, on decent volume.
Need to hear good news on tomorrow's quarterly call to breakout from this range. I'm mainly looking for 2 things; 1) positive guidance that the PCT subsidiary will be seeing increased revenues and will start generating income / positive cashflow within the next 3-6 months, and 2) an update on the status of partnering discussions in Japan. Current slide deck says goal is to "consummate" partnership. Market needs to hear CLBS is in final stage of negotiations to move higher.
|
|
|
Post by jckrdu on Nov 6, 2015 13:02:48 GMT
Restarted a position here at $1.12. Earnings call is 11/5, where we'll get more clarity on their financial position, burn rate... Still looking for Japan partnership news before end of year. Nice move off of $1.10ish to the $1.35 - $1.40 range where its been consolidating for the past few days, on decent volume.
Need to hear good news on tomorrow's quarterly call to breakout from this range. I'm mainly looking for 2 things; 1) positive guidance that the PCT subsidiary will be seeing increased revenues and will start generating income / positive cashflow within the next 3-6 months, and 2) an update on the status of partnering discussions in Japan. Current slide deck says goal is to "consummate" partnership. Market needs to hear CLBS is in final stage of negotiations to move higher.
Very good quarterly call yesterday. Revenues from PCT up 43% and quarterly burn rate significantly reduced. No definitive news on partnerships, but the financial update should be good enough to move the stock, IMO.
|
|
|
Post by ignorantsilver on Nov 15, 2015 15:57:16 GMT
Nice data shown in the call, but these guys must be running low on cash by now. How much is left? 20 million? Will that last any longer than 6 months? At what point do they appear desperate to partners? Just some questions I have for an otherwise attractive looking equity.
|
|
|
Post by jckrdu on Nov 16, 2015 15:14:23 GMT
Nice data shown in the call, but these guys must be running low on cash by now. How much is left? 20 million? Will that last any longer than 6 months? At what point do they appear desperate to partners? Just some questions I have for an otherwise attractive looking equity. Despite the positive progress announced on the call (increased revenues, significant reduction to burn rate) they likely will need more cash, which is why they put a $30 million dollar equity facility in place with Aspire (link below) in early November. They'll draw down those funds as needed, and that's probably the cause of the recent retrace to $1.15ish.
Hopefully this is the bottom, and pending news will take it higher. I'm looking for a Japan partnership and an announcement of another PCT deal... both could come at any time.
www.caladrius.com/investors/sec-filings/
|
|
|
Post by ignorantsilver on Nov 16, 2015 16:16:30 GMT
i really like their tech, but looks like a rather involved treatment. are there any estimates on cost of treatment? thanks
|
|